State of New Jersey
DEPARTMENT OF HEALTH
PO BOX 360
TRENTON, N.J. 08625-0360
www.nj.gov/health

PHILIP D. MURPHY
Governor

SHEILA Y. OLIVER
Lt. Governor

JUDITH M. PERSICHILLI, RN, BSN, MA
Commissioner

3rd REVISED STANDING ORDER FOR COVID-19 TESTING

AS TO COVERED FACILITIES

Control Number: 2020-02 (3rd Revised)

This revised standing order is issued pursuant to the New Jersey Emergency Health Powers Act, N.J.S.A. 26:13-1 et seq. ("Act"), Executive Order No. 103 (Murphy) declaring a public health emergency in New Jersey due to the Coronavirus disease 2019 ("COVID-19") outbreak, subsequent orders extending the public health emergency, Department of Health Executive Directive No. 20-034 and Executive Order Nos. 281 and 292 (Murphy). This revised standing order authorizes residents, staff, and visitors of a nursing home, assisted living residence, dementia care home, comprehensive personal care home, and residential health care facility licensed pursuant to P.L 1971, c. 136 (N.J.S.A. 26:2H-1 et seq.); and state Developmental Centers as listed in N.J.S.A. 30:1-7 (collectively, "covered facilities") to undergo testing for SARS-COV-2, the virus that causes COVID-19, without a prescription, subject to the terms set forth herein.

I. AUTHORIZATION

This revised standing order authorizes any healthcare provider, licensed pharmacist (to the extent authorized by the Department of Law and Public Safety, Division of Consumer Affairs), or trained personnel at a covered facility (collectively, "testers") to collect and process a SARS-COV-2 viral test for an individual in accordance with the conditions of this order. In addition, this standing order authorizes any healthcare provider or trained personnel at a covered facility to collect and perform SARS-COV-2 viral tests that are authorized for use in patient care settings at sites that possess a Clinical Laboratory Improvement Act ("CLIA") certificate or a CLIA certificate of waiver.

II. ELIGIBILITY

A. Resident or patient of a covered facility;

B. Staff member of a covered facility;

C. Visitor of a covered facility; and

D. Any individual entering a covered facility for a business or personal reason.

III. INFORMATION

A. Prior to collecting the specimen from the eligible individual, the tester shall provide information to the individual receiving the testing, which shall include but is not limited to the following:

1. Information on how and when to obtain test results;

2. Information for contacting the local health officiali[i] within the jurisdiction where the individual resides;

3. Information on next steps for the individual to take, including:

   a) Information on obtaining follow-up medical care or to address questions about a diagnosis if the individual tests positive for COVID-19;
   b) Information about actions to be taken in accordance with guidance as issued and/or amended by the Centers for Disease Control and Prevention ("CDC") and/or the New Jersey Department of Health.

IV. SPECIMEN COLLECTION, TESTING AND TEST RESULTS

A. Testers may collect a specimen for a SARS-COV-2 viral test that has been approved by the U.S. Food and Drug Administration ("FDA"), authorized by the FDA through an Emergency Use Authorization or approved by the New Jersey Clinical Laboratory Improvement Services as permitted by the FDA.[ii]

B. Preparation to collect a specimen:

1. Ensure correct testing materials according to manufacturer instructions for use and/or the laboratory who will be performing the test.
2. Ensure appropriate personal protective equipment for tester to administer the test, such as gloves, gowns, N95 or higher respirator (or surgical mask should a respirator not be available) and eye protection (goggles or face shield).

C. Instruction to collect a specimen:

1. By licensed healthcare provider, licensed pharmacist (to the extent authorized by the Department of Law and Public Safety, Division of Consumer Affairs), or trained, supervised personnel.
2. Follow manufacturer-specific and/or laboratory-specific instructions for specimen collection.
3. Follow CDC guidelines for Collecting, Handling, and Testing Clinical Specimens for Persons for Coronavirus Disease 2019, as amended and supplemented.[iii]

D. Testers may collect specimens and perform SARS-COV-2 viral tests that have been authorized by the FDA or authorized by the FDA through an Emergency Use Authorization for use in patient care settings under a CLIA certificate of waiver.

V. FOLLOW-UP

Test results must be reported to the individual by a representative of the testing location as soon as possible but no later than 2 days after the testing location's receipt of the test result. A positive result requires self-isolation per New Jersey Department of Health or local health department recommendations.

Covered facilities conducting COVID-19 testing pursuant to the Standing Order shall report the testing results to their local health department in a manner prescribed by the New Jersey Department of Health.

VI. TERM

A. This Third Revised Standing Order supersedes the Standing Orders issued on December 2, 2020 and August 24, 2022.

B. This Order shall take effect immediately. This standing order shall remain in force and effect until otherwise modified, supplemented, and/or rescinded or until the State of Emergency is no longer in effect, whichever is sooner.

New Jersey Department of Health
Issuing Official

Margaret C Fisher

Margaret Fisher, MD
Acting Deputy Commissioner
Public Health Services
New Jersey Department of Health
NPI Number: 1932165701
NJ License Number: 25MA07136300

9/7/22
Date

[i] Local Health Contact List, available at https://localhealth.nj.gov.
[ii] U.S. Food & Drug Administration, Emergency Use Authorizations, available at https://www.fda.gov/medicaldevices/emergency-situations-medical-devices/emergency-use-authorizations#covid19ivd.
[iii] CDC Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (COVID-19), available at https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinicalspecimens.html.